Aptose Biosciences' (APS.TO) acquisition by Hanmi has been further delayed as certain Korean regulatory approvals remain in progress, the company said on Friday.
The parties do not anticipate that the review will prevent closing and are working toward completing the arrangement in June, a statement said.
The company has received an additional advance of US$2.0 million from Hanmi as part of a US$11.9 million loan amended facility agreement announced last year. To date, Aptose has received US$9.9 million. The funds enable uninterrupted continuance of the Tuscany clinical trial with tuspetinib in combination with venetoclax and azacitidine for the frontline treatment of newly diagnosed acute myeloid leukemia (AML).
Aptose shares closed unchanged at $2.28 on Thursday on the Toronto Stock Exchange.